Human Milk Oligosaccharides: Role in Infant Health

2012 ◽  
pp. 209-219 ◽  
Author(s):  
Evelyn Jantscher-Krenn ◽  
Lars Bode
2019 ◽  
Vol 14 (2) ◽  
pp. 635-648 ◽  
Author(s):  
Melissa A. E. Lawson ◽  
Ian J. O’Neill ◽  
Magdalena Kujawska ◽  
Sree Gowrinadh Javvadi ◽  
Anisha Wijeyesekera ◽  
...  

AbstractDiet-microbe interactions play an important role in modulating the early-life microbiota, with Bifidobacterium strains and species dominating the gut of breast-fed infants. Here, we sought to explore how infant diet drives distinct bifidobacterial community composition and dynamics within individual infant ecosystems. Genomic characterisation of 19 strains isolated from breast-fed infants revealed a diverse genomic architecture enriched in carbohydrate metabolism genes, which was distinct to each strain, but collectively formed a pangenome across infants. Presence of gene clusters implicated in digestion of human milk oligosaccharides (HMOs) varied between species, with growth studies indicating that within single infants there were differences in the ability to utilise 2′FL and LNnT HMOs between strains. Cross-feeding experiments were performed with HMO degraders and non-HMO users (using spent or ‘conditioned’ media and direct co-culture). Further 1H-NMR analysis identified fucose, galactose, acetate, and N-acetylglucosamine as key by-products of HMO metabolism; as demonstrated by modest growth of non-HMO users on spend media from HMO metabolism. These experiments indicate how HMO metabolism permits the sharing of resources to maximise nutrient consumption from the diet and highlights the cooperative nature of bifidobacterial strains and their role as ‘foundation’ species in the infant ecosystem. The intra- and inter-infant bifidobacterial community behaviour may contribute to the diversity and dominance of Bifidobacterium in early life and suggests avenues for future development of new diet and microbiota-based therapies to promote infant health.


Author(s):  
Josh M Jorgensen ◽  
Rebecca Young ◽  
Per Ashorn ◽  
Ulla Ashorn ◽  
David Chaima ◽  
...  

ABSTRACT Background Human milk oligosaccharides (HMOs) and bioactive proteins likely benefit infant health, but information on these relationships is sparse. Objective We aimed to examine associations of milk content of HMOs and bioactive proteins with incidence and longitudinal prevalence of infant morbidity (any illness, fever, diarrhea, acute respiratory infection, and loss of appetite) and markers of inflammation [C-reactive protein (CRP) and α-1-acid glycoprotein (AGP)]. These are secondary analyses of a randomized controlled trial. Methods Breast milk samples at 6 mo postpartum (n = 659) were analyzed to quantify absolute abundance of HMOs, relative abundance of fucosylated HMOs, sialylated HMOs, and 51 individual HMOs, and concentrations of 6 bioactive proteins (lactalbumin, lactoferrin, lysozyme, antitrypsin, IgA, and osteopontin). We examined associations of these constituents with infant morbidity from 6 to 7 and 6 to 12 mo, and CRP and AGP at 6 and 18 mo, considering maternal secretor status (FUT2 gene positive) and adjusting for covariates and multiple hypothesis testing. Results Among secretors there were positive associations between total HMOs and longitudinal prevalence of fever (p = 0.032), fucosylated HMOs and incidence of diarrhea (p = 0.026), and lactoferrin and elevated CRP at 18 mo (p = 0.011). Among non-secretors, there were inverse associations between lactoferrin and incidence of fever (p = 0.007), osteopontin and longitudinal prevalence of lost appetite (p = 0.038), and fucosylated HMOs and incidence of diarrhea (p = 0.025), lost appetite (p = 0.019), and concentrations of AGP and CRP at 6 mo (p = 0.001 and 0.010); and positive associations between total HMOs and incidence of lost appetite (p = 0.024) and elevated CRP at 18 mo (p = 0.026), lactalbumin and incidence of diarrhea (p = 0.006), and lactoferrin and elevated CRP at 18 mo (p = 0.015). Conclusion Certain HMOs and bioactive proteins were associated with infant morbidity and inflammation, particularly among non-secretors. Further research is needed to elucidate causality of these relationships. Registered at clinicaltrials.gov as NCT01239693. This trial was registered at clinicaltrials.gov as NCT01239693.


2020 ◽  
Vol 11 ◽  
Author(s):  
Lianghui Cheng ◽  
Mensiena B. G. Kiewiet ◽  
Madelon J. Logtenberg ◽  
Andre Groeneveld ◽  
Arjen Nauta ◽  
...  

Pathogens ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 739
Author(s):  
Ulvi K. Gürsoy ◽  
Krista Salli ◽  
Eva Söderling ◽  
Mervi Gürsoy ◽  
Johanna Hirvonen ◽  
...  

Human milk oligosaccharides (HMOs), the third largest solid fraction in human milk, can modulate inflammation through Toll-like receptor signaling, but little is known about their immunomodulatory potential in the oral cavity. In this study, we determined whether the HMOs 2’-fucosyllactose (2’-FL) and 3-fucosyllactose (3-FL) regulate human-beta defensin (hBD)-2 and -3, cathelicidin (hCAP18/LL-37), and cytokine responses in human gingival cells using a three-dimensional oral mucosal culture model. The model was incubated with 0.1% or 1% 2’-FL and 3-FL, alone and in combination, for 5 or 24 h, and hBD-2, hBD-3, and hCAP18/LL-37 were analyzed by immunohistochemistry. The expression profiles of interleukin (IL)-1, IL-1RA, IL-8, and monocyte chemoattractant protein (MCP)-1 were determined by LUMINEX immunoassay. The combination of 1% 2’-FL and 1% 3-FL, and 1% 3-FL alone, for 24 h upregulated hBD-2 protein expression significantly (p < 0.001 and p = 0.016, respectively). No changes in the other antimicrobial peptides or proinflammatory cytokines were observed. Thus, 3-FL, alone and in combination with 2´-FL, stimulates oral mucosal secretion of hBD-2, without effecting a proinflammatory response when studied in an oral mucosal culture model.


Sign in / Sign up

Export Citation Format

Share Document